Form 8-K - Current report:
SEC Accession No. 0001558370-22-004821
Filing Date
2022-03-31
Accepted
2022-03-31 07:01:58
Documents
14
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20220331x8k.htm   iXBRL 8-K 40825
2 EX-99.1 plx-20220331xex99d1.htm EX-99.1 176288
3 GRAPHIC plx-20220331xex99d1001.jpg GRAPHIC 3809
  Complete submission text file 0001558370-22-004821.txt   361132

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20220331.xsd EX-101.SCH 3195
5 EX-101.LAB plx-20220331_lab.xml EX-101.LAB 16162
6 EX-101.PRE plx-20220331_pre.xml EX-101.PRE 10907
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20220331x8k_htm.xml XML 4870
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 22789083
SIC: 2836 Biological Products, (No Diagnostic Substances)